Subscribe

Spago Nanomedical AB (publ) (SPAGO.ST)

SEK0.11 -0.01 (-4.76%)
SE STO Healthcare Biotechnology
Address Scheelevägen 22 223 63
Lund, SE
CEO Mats Hansen
Website spagonanomedical.se
IPO 2013-01-16
ISIN SE0004899474

Explore sections of this company profile

Description

Operating primarily in Sweden, Spago Nanomedical AB (publ) is dedicated to pioneering nanomedicines for both the diagnosis and treatment of cancer. The company is actively pursuing two key projects: the SpagoPix initiative, centered on SN132D, a gadolinium-free MRI contrast agent developed for imaging breast and pancreatic cancers; and the Tumorad project, which is advancing SN201, a radionuclide therapy intended for managing advanced and metastatic forms of cancer. Originally established as Spago Imaging AB (publ), the company adopted its current name, Spago Nanomedical AB (publ), in May 2014. Founded in 1999, its base of operations is situated in Lund, Sweden.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
SEK0.11 -0.01 (-4.76%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
529.7K
Beta
1.30
Float Shares
116.93M
Free Float %
31.5%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.91% -13.16% -6.49% -8.26% +0.45% +0.91% -47.14% -85.12% -98.46% -99.29% -99.05%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
0.11
DCF (Unlevered) 0.05 -57.7%
DCF (Levered) 0.05 -58.7%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM)
Rating 2026-05 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
2.03
Grey zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Biotechnology: +1.6%
    -77.1% Q1'26: -93.5% (vs Q1'25)
  • ✗
    EPS growth Biotechnology: +29.7%
    +35.6% ★ Q1'26: +51.9% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Biotechnology: +16.2%
    +60.6% Q1'26: +0.0% (vs Q1'25)
  • ✗
    EBIT margin Biotechnology: +0.0%
    -6,076.4% Q1'26: -35,995.5% (vs Q1'25)
  • ✗
    ROIC Biotechnology: -16.1%
    -2,472.4% Q1'26: +1,838.4% (vs Q1'25)
  • ✗
    Share dilution Biotechnology: -3.4%
    +26.9% Q1'26: +90.0% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (1.31) × ERP
WACC = 100% × Ke + 0% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 0.05 Current price: 0.11
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2016
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana.
Revenue
58.0K
est: 4.0K (+1,350.0%)
660.0K
est: 1.00M (-34.0%)
1.05M
est: 1.00M (+5.4%)
1.20M
est: 6.28M (-80.8%)
1.91M
est: 7.00M (-72.7%)
437.0K
est: 1.00M (-56.3%)
1.00M
1.00M – 1.00M
+0.0% YoY
1.00M
1.00M – 1.00M
+0.0% YoY
1.00M
1.00M – 1.00M
+0.0% YoY
EBITDA
-7.02M
est: -4.0K (-175,500.0%)
-38.69M
est: -1.00M (-3,769.1%)
-38.73M
est: -1.00M (-3,772.9%)
-42.22M
est: -6.28M (-572.8%)
-33.40M
est: -7.00M (-377.2%)
-26.39M
est: -1.00M (-2,538.7%)
-1.00M
-1.00M – -1.00M
+0.0% YoY
-1.00M
-1.00M – -1.00M
+0.0% YoY
-1.00M
-1.00M – -1.00M
+0.0% YoY
EBIT
-7.29M
est: -4.0K (-182,125.0%)
-39.07M
est: -1.00M (-3,806.7%)
-39.09M
est: -1.00M (-3,808.5%)
-42.51M
est: -6.28M (-577.3%)
-33.71M
est: -7.00M (-381.6%)
-26.55M
est: -1.00M (-2,555.4%)
-1.00M
-1.00M – -1.00M
+0.0% YoY
-1.00M
-1.00M – -1.00M
+0.0% YoY
-1.00M
-1.00M – -1.00M
+0.0% YoY
Net Income
-7.54M
est: -237.34M (+96.8%)
-39.08M
est: -201.15M (+80.6%)
-39.31M
est: -236.64M (+83.4%)
-42.22M
est: -71.40M (+40.9%)
-32.51M
est: -26.49M (-22.7%)
-26.55M
est: -13.25M (-100.5%)
-26.17M
-26.17M – -26.17M
-97.6% YoY
-26.17M
-26.17M – -26.17M
+0.0% YoY
-37.39M
-37.39M – -37.39M
-42.9% YoY
SGA
4.82M
est: 54.0K (+8,834.1%)
7.54M
est: 13.49M (-44.1%)
8.07M
est: 13.49M (-40.2%)
23.67M
est: 65.54M (-63.9%)
25.71M
est: 73.10M (-64.8%)
—
est: 10.44M (-100.0%)
10.44M
10.44M – 10.44M
+0.0% YoY
10.44M
10.44M – 10.44M
+0.0% YoY
10.44M
10.44M – 10.44M
+0.0% YoY
EPS
-0.43
est: -0.80 (+47.1%)
-0.46
est: -0.68 (+32.4%)
-0.29
est: -0.80 (+63.8%)
-0.21
est: -0.19 (-10.2%)
-0.11
est: -0.07 (-55.6%)
-0.07
est: -0.04 (-100.4%)
-0.07
-0.07 – -0.07
-97.6% YoY
-0.07
-0.07 – -0.07
+0.0% YoY
-0.10
-0.10 – -0.10
-42.9% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 C- 1/5 3/5 1/5 1/5 1/5 1/5 2/5
2026-05-28 C- 1/5 3/5 1/5 1/5 1/5 1/5 2/5
2026-05-27 C- 1/5 3/5 1/5 1/5 1/5 1/5 2/5
2026-05-26 C- 1/5 3/5 1/5 1/5 1/5 1/5 2/5
2026-05-25 C- 1/5 3/5 1/5 1/5 1/5 1/5 2/5
2026-05-22 C- 1/5 3/5 1/5 1/5 1/5 1/5 2/5
2026-05-21 C- 1/5 3/5 1/5 1/5 1/5 1/5 2/5
2026-05-20 C- 1/5 3/5 1/5 1/5 1/5 1/5 2/5
2026-05-19 C- 1/5 3/5 1/5 1/5 1/5 1/5 2/5
2026-05-18 C- 1/5 3/5 1/5 1/5 1/5 1/5 2/5
2026-05-15 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-05-13 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-05-12 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-05-11 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-05-08 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-05-07 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-05-06 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-05-05 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-05-04 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-04-30 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-04-29 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-28 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-27 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-24 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-23 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-22 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-21 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-20 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-17 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-16 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-16.02M
OE per share TTM
-0.05
Owner's Yield
-21.82%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
97.7%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-20.4K
Shares Outstanding
370.92M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Mats Hansen Chief Executive Officer 3M —
Hanna Olsson Chief Financial Officer — female
Paul Hargreaves Chief Development Officer — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology